A modular and controllable T cell therapy platform for acute myeloid leukemia.

Saved in:
Bibliographic Details
Title: A modular and controllable T cell therapy platform for acute myeloid leukemia.
Authors: Benmebarek MR; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Cadilha BL; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Herrmann M; Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany., Lesch S; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Schmitt S; Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany., Stoiber S; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Darwich A; Mucosal Immunology and Microbiota Lab, Humanitas Clinical and Research Center, Milan, Italy., Augsberger C; Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany., Brauchle B; Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany., Rohrbacher L; Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany., Oner A; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Seifert M; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Schwerdtfeger M; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Gottschlich A; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Rataj F; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany., Fenn NC; Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany., Klein C; Roche Innovation Center Zurich, Schlieren, Switzerland., Subklewe M; Department of Medicine III, Klinikum der Universität München, LMU, Munich, Germany.; Laboratory for Translational Cancer Immunology, Gene Center, LMU Munich, Munich, Germany.; German Center for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany., Endres S; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany.; German Center for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany.; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany., Hopfner KP; Gene Center, LMU, Munich, Germany., Kobold S; Center of Integrated Protein Science Munich (CIPS-M) and Division of Clinical Pharmacology, Department of Medicine IV, Klinikum der Universität München, LMU, Munich, Germany. Sebastian.kobold@med.uni-muenchen.de.; German Center for Translational Cancer Research (DKTK), Partner Site Munich, Munich, Germany. Sebastian.kobold@med.uni-muenchen.de.; Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany. Sebastian.kobold@med.uni-muenchen.de.
Source: Leukemia [Leukemia] 2021 Aug; Vol. 35 (8), pp. 2243-2257. Date of Electronic Publication: 2021 Jan 07.
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5551
DOI:10.1038/s41375-020-01109-w